Relative retention time and ion ratios were used as identification parameters. Limits of detection (LOD) in blood were 5 pg/mL for LSD and iso-LSD and 10 pg/mL for nor-LSD and O-H-LSD. In urine, the LOD was 10 pg/mL for all analytes. Limits of quantitation (LOQ) in blood and urine were 20 pg/mL for LSD and iso-LSD and 50 pg/mL for nor-LSD and O-H-LSD. The method was linear, accurate, and precise from 10 to 2000 pg/mL in blood and 20 to 2000 pg/mL in urine for LSD and iso-LSD and from 20 to 2000 pg/mL in blood and 50 to 2000 pg/mL in urine for nor-LSD and O-H-LSD with a coefficient of determination (R 2 ) ≥ ≥ 0.99. The method was applied to blinded biological control samples and biological samples taken from a suspected LSD user. This is the first reported detection of O-H-LSD in blood from a suspected LSD user.
Introduction
The analysis of lysergic acid diethylamide (LSD) in biological fluids has been a challenge. LSD is generally taken in small doses (1) , is metabolized rapidly (2) , has a short half-life (3), and is an unstable compound (4) . The biggest challenge analytically is related to the low concentration of LSD and its metabolites in biological fluids. Therefore, a highly sensitive method is needed to detect and confirm the presence of LSD and its metabolites. To increase the window of detection for LSD use, recent methods have been targeting the metabolites of LSD because they have longer half-lives and are present in higher concentrations than LSD. The half-life of N-demethyl-LSD (nor-LSD) is 10 h (5), and LSD has a half-life of 5.1 h (6). More recently, 2-oxo-3-hydroxy-LSD (O-H-LSD) was determined to be a major metabolite of LSD (7), and it has been reported in concentrations of up to 25 times higher than LSD in the urine (8) .
Additionally, previous methods have also targeted the isomer of LSD. The diastereoisomer impurity (iso-LSD) is formed during the production of illicit LSD from lysergic acid (9) . iso-LSD can also form when LSD is exposed to basic aqueous solutions and increased temperatures (4, 10) , ultimately reaching an LSD/iso-LSD ratio of 9:1 in the sample (10, 11) .
Iso-LSD, nor-LSD, and O-H-LSD do not have any psychoactive
properties, but their presence in biological fluids is an indication of LSD use.
A number of gas chromatography-mass spectrometry (GC-MS) methods have been developed to identify LSD (12) (13) (14) (15) . However, the detection of LSD using GC-MS has its challenges. LSD undergoes irreversible adsorption during the chromatographic process, is relatively nonvolatile, and is not stable at the elevated temperatures associated with GC (12) . Furthermore, sample preparation is laborious, requiring a derivatization step (12, 16) . Because of the difficulties in detecting LSD by GC-MS and the increase in popularity of liquid chromatography (LC), recent identification methods developed for LSD analysis have used LC-MS (8, (16) (17) (18) (19) (20) (21) (22) (23) or LC-MS-MS (9, (23) (24) (25) (26) (27) .
The Royal Canadian Mounted Police (RCMP) Forensic Science and Identification Services (FS&IS) has been involved in the identification of LSD in biological samples for the past 15 years. An enzyme-linked immunosorbant assay (ELISA) from Immunalysis ® (Pomona, CA) is currently being used by the RCMP FS&IS as a rapid screening method for LSD. In 1997, the RCMP FS&IS developed a confirmatory GC-MS method using the
Standard solutions
Individual stock solutions of LSD, iso-LSD, nor-LSD, and O-H-LSD, each at a concentration of 500 ng/mL, were prepared in ACN. Using the stock solutions, two working solutions (1 and 20 ng/mL) containing all analytes (i.e., LSD, iso-LSD, nor-LSD, and O-H-LSD) were prepared in ACN. The working solutions were then used to prepare nine calibrators (5, 10, 20, 50, 100, 400, 800, 1600, and 2000 pg/mL). Each calibrator contained all four analytes spiked into drug-free porcine blood or synthetic urine. The working solutions were also used to prepare control samples (50, 500, and 1500 pg/mL) containing all analytes spiked into drug-free porcine blood or synthetic urine. A 500 ng/mL internal standard (ISTD) (LSD-d 3 ) stock solution was prepared in ACN and further diluted with ACN to prepare a 20 ng/mL internal standard working solution. LSD-d 3 was used as the internal standard for all analytes.
LC conditions
A Waters (Milford, MA) Acquity UPLC with an autosampler using an Acquity UPLC Bridged Ethyl Hybrid (BEH) C18 (2.5 × 50 mm, 1.7 µm, Waters) column was used for chromatographic separation. Separation was conducted at 30°C. A gradient elution was conducted using 20 mM ammonium acetate buffer (pH 4.0) and ACN at a flow rate of 0.2 mL/min. A gradient of buffer/ACN (90:10) was held for 1 min, followed by a linear step gradient to buffer/ACN (75:25) for 10 min, and held for 1 min. The column was then equilibrated for 2 min, giving a total run time of 15 min.
MS conditions
A Waters Quattro Premier™ tandem-quadrupole MS equipped with a Z-spray™ ion source was coupled to the UPLC system. Atmospheric pressure ionization (API) was done via positive electrospray ionization (ESI). The electrospray probe tip potential was set at 3.00 kV. The source and desolvation temperatures were set at 120 and 350°C, respectively. The cone and desolvation gas flows were set at 110 and 747 L/h, respectively. The collision gas (argon) flow and pressure were set at 0.28 mL/min and 4.21 × 10 -3 mbar, respectively. The MS was run in multiple reaction monitoring (MRM) mode with a dwell time of 0.20 s (interscan delay of 0.01 s) ( Table I) .
Sample preparation
Sample preparation procedure was adapted from previously published methods (21, 27) . To 1 mL of each sample, 50 µL of LSD-d 3 ISTD working solution (20 ng/mL) was added, and the sample was vortex mixed for 10 s. Then 500 µL of 1 M ammonium acetate buffer (pH 9.0) was added, and the sample was vortex mixed again for 10 s. Each sample was extracted with 5 mL of dichloromethane/isopropyl alcohol (85:15). The tube was capped, manually shaken for 5 s, and then placed on a flatbed shaker (Eberbach, Ann Arbor, MI) at low speed for 20 min. Each tube was centrifuged at 3500 rpm for 15 min. The aqueous (top) layer was discarded. The organic (bottom) layer was transferred to a clean tube and evaporated to dryness (N 2 stream, room temperature). The residue was reconstituted in 100 µL of 20 mM ammonium acetate buffer (pH 4.0)/ACN (80: 20) , and 20 µL of sample was injected onto the UPLC system.
Validation procedure
Three sets of calibrators (including blanks) were prepared fresh daily and extracted as described here previously, on three separate days. Data collection, peak integration, and weighted (1/x 2 ) linear regression were performed using MassLynx™ version 4.0 software (Waters). Nominal concentration versus peak-area ratio values were plotted to define the calibration curve. A suitable linear range was determined by evaluating the accuracy (% bias) of calculated results. Six sets of controls (50, 500, and 1500 pg/mL) were prepared fresh daily and extracted to assess intraday accuracy and precision. This was then repeated on three separate days to assess interday accuracy and precision. Control results were calculated from the equation as determined by the weighted (1/x 2 ) linear regression of the calibration curve. The accuracy of the method was determined by % bias. The precision of the method was determined by the coefficient of variation (%CV).
Limits of detection (LOD) and quantitation (LOQ) were assessed by determining the peak-to-peak signal-to-noise ratio (S/N) using the MassLynx™ version 4.0 software. LOQ must also demonstrate acceptable accuracy and precision. Another parameter assessed was selectivity. Six different sources of drug-free urine and blood matrix were extracted and analyzed. Each source of drug-free urine and blood was then tested for interference at the LOQ.
The percentage recovery was assessed in two matrices (i.e., porcine blood and synthetic urine) by preparing two sets of samples in each matrix. Each set contained all analytes and was prepared in replicates of six at 50 and 1500 pg/mL. Samples in the first set were prepared by adding the appropriate volume of working solution to drug-free matrix, and then the samples were extracted. Samples in the second set were prepared by extracting drug-free matrix then adding the appropriate volume of working solution to the extracts. The peak-area ratios of samples in the first set were compared to the samples in the second set to determine percentage recovery.
Matrix effect was assessed by using a previously published experimental procedure (28) . Five different lot numbers of drugfree synthetic urine and one drug-free human urine sample were evaluated. Drug-free porcine blood and drug-free human blood (five sources) were also evaluated.
For further confirmation of the analytes, other factors such as relative retention time (RRT) and ion ratios were included. The ion ratio was derived from the peak area of the product ion in one MRM divided by the peak area of another product ion in a second MRM.
Results and Discussion
Optimization of the MS conditions was done by direct infusion of the drug standards (2 µg/mL) at 20 µL/min through a syringe pump into a T piece with mobile phase. MS parameters were adjusted to maximize sensitivity of product ions produced by collision-induced dissociation of protonated ions.
Linearity and range
The 
Accuracy and precision
The accuracy was deemed acceptable if the % bias of the calculated results of the control samples were ± 15% and ± 20% at LOQ of the nominal concentration. The precision was deemed acceptable if the %CV of the calculated results of the control samples were less than 15% and 20% at LOQ. Quantitations are done mainly on blood samples. Urine samples are used for qualitative analysis. As a result, for the validation study quantitative analysis for blood was conducted using a full calibration curve with six points, whereas semi-quantitative analysis for urine was conducted using a three-point calibration curve. Both inter-and intraday accuracy and precision for all analytes in both urine and blood were within acceptable limits. The accuracy and precision for all analytes in both blood and urine ranged from -13 to 4% bias and 3 to 14% CV, respectively.
LOD and LOQ
LOD and LOQ are defined as where the S/N is greater than 3:1 and 10:1, respectively. In addition to a S/N greater than 10:1, the LOQ must also show acceptable accuracy (± 20% bias) and precision (< 20% CV). In urine, the LOD was 10 pg/mL for all analytes, and the LOQ was 20 pg/mL for LSD and iso-LSD and 50 pg/mL for nor-LSD and O-H-LSD. In blood, the LOD was 5 pg/mL for LSD and iso-LSD and 10 pg/mL for nor-LSD and O-H-LSD, and the LOQ was 20 pg/mL for LSD and iso-LSD and 50 pg/mL for nor-LSD and O-H-LSD. LOD and LOQ values in this study showed very good sensitivity, and this can most likely be attributed to the highly efficient UPLC columns. Chromatography can affect the LOD and LOQ wherein better peak shape gives a higher S/N ratio, resulting in a lower LOD and LOQ (29) .
Selectivity
The Food and Drug Administration (FDA) recommends that the LOQ have at least five times the response compared to the blank (30) . Six different sources of blank urine and blood were extracted and analyzed, and no interferences were found at the LOQ.
Recovery
Percentage recoveries of LSD and related analytes ranged from 74 to 88% in urine and 61 to 69% in blood. The recov-eries found in this study were similar to the liquid-liquid extraction (LLE) methods reported in the literature (21, 27) . The percentage recoveries were reproducible with a %CV range of 3.9 to 11.4% in urine and 2.9 to 8.1% in blood for all analytes. Both high (1500 pg/mL) and low (50 pg/mL) concentrations of each analyte also showed similar percentage recoveries.
Matrix effect
Both urine and blood demonstrated similar absolute matrix effect at both the high (1500 pg/mL) and low (50 pg/mL) concentrations. LSD, iso-LSD, O-H-LSD, and LSD-d 3 showed slight ion suppression, whereas nor-LSD showed slight ion enhancement. One ion suppression study done by Johansen and Jensen (9) was conducted by injecting extracted spiked porcine blood extracts through a syringe pump into a T piece with mobile phase. Authors in that study found no evidence of ion suppression for LSD and iso-LSD and stated that the deuterated ISTD corrected for any possible suppression of ions.
Even though the absolute matrix effect of nor-LSD was different compared to the other analytes, this does not necessarily indicate that the bioanalytical method was invalid. If the relative matrix effect exhibits the same pattern for the analyte and the ISTD in all sources of matrix studied, the analyte to ISTD ratio should not be affected (28) . The relative matrix effect, defined as the comparison of matrix effect values between different sources of the matrix, showed no significant difference (p > 0.05, F test) between the variances of the peak-area ratio of neat standards in ACN versus blood and urine. The relative matrix effect of all analytes was not shown to differ significantly, confirming that the matrix effect had no effect on the quantitation of LSD, iso-LSD, nor-LSD, and O-H-LSD.
Other qualitative parameters
The RRTs of all analytes were precise (%CV ≤ 1.7%) over three days of analysis in both urine and blood. The RRT was deemed acceptable as a parameter of confirmation if the control samples did not differ by more than 2% (% bias) relative to the calibrators (31). MRM ion ratios of the calibrators were found to be precise, and the ion ratios of the control samples were found to be accurate (± 30% bias) relative to the mean ion ratio of the calibrators. The ion ratios were also found to be concentration dependent. The precision at the low (50 pg/mL) concentration was less than at the higher (1500 pg/mL) concentration, even more so for O-H-LSD. Because it was demonstrated that the ion ratios were concentration dependent, a ± 30% bias was chosen for the acceptance criteria (32) .
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Control samples blinded to the analysts
To test the reliability of this method, eight control samples (four urine and four blood) were prepared by another laboratory using drug-free human urine and blood (McKay, Pharmalytics, Saskatoon, SK, Canada). The actual concentrations in these control samples were blinded to the analysts. Each control sample was extracted in duplicate. Analysis was conducted by two different analysts on two different days. The results obtained with the UPLC-MS-MS method are summarized in Table II .
Case study
This validated method was used to analyze samples from a 1995 case that was found to be positive for LSD using radioimmunoassay (RIA). The scenario provided was as follows: a 19-year-old male leaped out of a 16th floor window and landed on the 5th floor of a parking garage. The ultimate cause of death was "multiple blunt force injuries". His friends said that he might have taken LSD. When the father was questioned, he indicated that he was not aware of any specific history of drug abuse, depression, or thoughts of suicide by his son. At autopsy, four samples were collected: 1. femoral blood collected in a grey stopper (potassium oxalate, sodium fluoride) Vacutainer, 2. subclavian blood collected in a plastic screw-top container, 3. vitreous humor collected in a Vacutainer with no additives, and 4. urine collected in a grey-stoppered (potassium oxalate, sodium fluoride) Vacutainer. In 1995, an alcohol and routine toxicology screen (immunoassay and GC-MS) were conducted. No alcohol or other common drugs were identified in the routine screen except for 3 mg/L acetaminophen in the blood. Based on the history, an LSD RIA kit was obtained and run with appropriate controls. All samples "screened positive". The final 1995 toxicology report noted a "presumptive" LSD result but that no confirmatory method was available. After the analysis was completed in 1995, the samples were refrigerated for about 2-4 months and then kept frozen in a -50°C freezer for 10 years.
In December 2005, all samples were extracted in duplicate and analyzed using the method described earlier. The results obtained in the case samples are summarized in Figure 1 and Table III . Even 10 years after collection, LSD and metabolites were still detectable. However, because no quantitation was conducted on the samples 10 years ago, the stability of the analytes cannot be assessed. Nonetheless, the results show that LSD and metabolites can still be detected if kept in a frozen state. To our knowledge, this is the first time that O-H-LSD has been detected and confirmed in blood. The majority of the methods published for O-H-LSD have only attempted analysis in urine (8, 23, 24) . Methods that have attempted to confirm LSD and metabolites, including O-H-LSD, in blood were unable to detect O-H-LSD even when the blood was positive for LSD (21, 27) . Previous LC-MS and LC-MS-MS methods may Time (min) have been unsuccessful in detecting O-H-LSD in blood because of a lack of sensitivity in the extraction. One method using an Agilent HPLC coupled to a mass selective detector was unable to detect O-H-LSD in blood (21) . When blood spiked with O-H-LSD was extracted, percentage recovery was 32 to 42%, compared to 69 to 73% in urine. The low recovery in blood is likely due to the solid-phase extraction step done after the initial LLE. The LOD and LOQ (400 pg/mL) were only determined for urine. Nonetheless, an LOD and LOQ of 400 pg/mL for O-H-LSD would not have been sufficiently sensitive to detect O-H-LSD in this case sample.
Like the blind control samples, several of the results for LSD and O-H-LSD from the case sample were reported as > 1500 pg/mL because the concentration was higher than the highest calibrator (1500 pg/mL). Extrapolating the calibration curve showed that O-H-LSD was present in urine at higher concentrations than LSD. Others have found that the concentration of O-H-LSD is 16 to 25 times higher than that of LSD (8, 23) .
This method was not validated for a vitreous humor matrix. Because it was shown that vitreous humor samples may also contain LSD, validating the method for vitreous humor could be done in future experiments. Favretto et al. (33) validated an LC-MS-MS (LCQ Duo ion trap MS) method for LSD, iso-LSD, nor-LSD, and O-H-LSD in vitreous humor. They reported an LOD and LOQ of 10 and 20 pg/mL, respectively, for LSD and nor-LSD. That method was also used for a vitreous humor case sample. Results were 2.9 ng/mL LSD and 2.2 ng/mL nor-LSD.
Conclusions
An accurate, precise, selective, and sensitive UPLC-MS-MS method was validated to identify, confirm, and quantitate LSD, iso-LSD, nor-LSD, and O-H-LSD in both urine and blood. Compared with the GC-MS method previously utilized by the RCMP since 1997, the UPLC-MS-MS method was more suitable for the analysis of LSD and metabolites in blood and urine, providing better sensitivity and greater ease of analysis while using a smaller sample volume.
To the best of our knowledge, there are no published validated methods for the simultaneous confirmatory and quantitative analysis of LSD, iso-LSD, nor-LSD, and O-H-LSD in urine and blood. Furthermore, compared with other published methods, the LOD and LOQ obtained in this study for O-H-LSD and nor-LSD for both blood and urine are among the lowest. In conclusion, a validated UPLC-MS-MS method is now available for confirming the use of LSD in blood and urine.
